F.D.A. Approves Zepbound: A Breakthrough Weight Loss Drug to Treat Obstructive Sleep Apnea
The Food and Drug Administration (FDA) has approved Zepbound, a groundbreaking weight loss drug, as the first prescription medication specifically designed to treat obstructive sleep apnea (OSA). Manufactured by Eli Lilly, Zepbound is authorized for individuals with obesity and moderate to severe OSA. This approval marks a significant milestone in the medical field, offering hope … Read more
